<DOC>
	<DOCNO>NCT00003663</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining monoclonal antibody rituximab dexamethasone may kill cancer cell . PURPOSE : Phase II trial study effectiveness rituximab dexamethasone treating patient recurrent refractory indolent non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Dexamethasone Treating Patients With Recurrent Refractory Indolent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect rituximab dexamethasone patient recurrent refractory indolent non-Hodgkin 's lymphoma . II . Determine objective tumor response rate duration response 2 month initiation therapy , percentage patient progressive disease . III . Determine maximum response , duration response , progression free interval patient progress 4 week therapy . IV . Determine failure-free overall survival patient regimen . V. Compare response rate survival rate result similar patient ( historical concurrent ) receive 4 week rituximab without dexamethasone , patient receive maintenance rituximab . OUTLINE : Patients receive dexamethasone IV follow rituximab IV day 1 , 8 , 15 , 22 one course . Two month initiate treatment , patient evaluate disease progression . Patients stable respond disease may receive monthly dexamethasone rituximab therapy 10 additional month . Patients follow every 3 month 2 year , every 6 month year 3-4 , yearly 5 year . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III IV , recurrent refractory , indolent B cell nonHodgkin 's lymphoma follow type : Working Group Formulation A ( small cell lymphocytic ) Working Group Formulation B , C , D ( follicular ) Must relapse prior chemotherapy At least 1 lymph node visceral lesion least 2 cm diameter PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Lymphocyte count le 5,000/mm3 Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception No active infection HIV negative No hepatitis B C No concurrent life threaten condition PRIOR CONCURRENT THERAPY : Biologic therapy : No prior monoclonal antibody therapy lymphoma ( e.g. , rituximab ) Chemotherapy : See Disease Characteristics Endocrine therapy : No concurrent corticosteroid and/or epinephrine ( unless anaphylactic shock ) Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>